A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This trial will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of
multiple oral doses of OPC-167832 in subjects with uncomplicated, smear-positive,
drug-susceptible pulmonary tuberculosis (TB).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.